Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
MDNA-11 by Medicenna Therapeutics for Lung Adenocarcinoma: Likelihood of Approval
MDNA-11 is under clinical development by Medicenna Therapeutics and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase...